Expression studies of two vasopressin V2 receptor gene mutations, R202C and 804insG, in nephrogenic diabetes insipidus  by Tsukaguchi, Hiroyasu et al.
Kidney International, Vol. 48 (1995), pp. 554—562
Expression studies of two vasopressin V2 receptor gene
mutations, R202C and 8O4insG, in nephrogenic diabetes insipidus
HIROYASU TSUKAGUCHI, HIRoxI MATSUBARA, and Mrrsuo INADA
Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan
Expression studies of two vasopressin V2 receptor gene mutations,
R202C and SO4insG, in nephrogenic diabetes insipidus. Nephrogenic
diabetes insipidus (NDI) is a rare X-linked disorder associated with renal
tubule resistance to arginine vasopressin (AVP). To understand the
mechanisms of AVP resistance underlying this disorder, we have analyzed
the vasopressin V2 receptor gene in two unrelated Japanese kindreds with
NDI and expressed the mutants to characterize their functional proper-
ties. Direct sequencing revealed two V2 receptor gene mutations: a
missense mutation from Arg202 to Cys in the third extracellular domain
(R202C) and a single base insertion (ci) in two consecutive GGG triplets
(nucleotide 804 to 809) in the third cytoplasmic domain, resulting in a
frame shift with premature termination at codon 258 (8O4insG). Transient
expression study with COS-7 cells showed that R202C mutation reduced
both binding affinity (15%) and capacity (30%), while 8O4insG mutation
abolished binding ability. For further evaluation of the binding ability of
the R202C mutant, we expressed the mutants in Chinese hamster ovary
(CHO) cells. Although the mutant cell lines produced V2 receptor mRNA
comparable levels to the wild-type receptor cell lines, R202C mutant cell
lines had no binding ability. Our results suggest an introduction of a new
cysteine residue in the extracellular domain and a receptor truncation
removing one third of the carboxyl terminus could impair ligand binding
activity of the V2 receptor through a post-transcriptional mechanism,
thereby causing AVP resistance in the NDI patients.
Nephrogenic diabetes insipidus (NDI) is a rare inherited dis-
order characterized by the inability to concentrate urine due to
renal tubular resistance to arginine vasopressin (AVP) [1]. Af-
fected individuals typically have hypoosmotic polyuria soon after
birth. In the neonate and infant with NDI, however, poor feeding,
poor weight gain, and unexplained recurrent fever are often initial
manifestations. Unless recognized and treated early, persistent
severe dehydration may lead to growth and mental retardation, or
death. Nevertheless, it has a good prognosis, provided that
dehydration and hypernatremia are prevented. Therefore, early
diagnosis and management which ensures an adequate fluid
intake are crucial for affected male individuals. In most cases of
NDI, the mode of inheritance follows an X chromosome-linked
recessive pattern [1]. On the other hand, a sporadic case or
autosomal dominant/recessive inheritance had been described.
Recently, water channel aquaporin-2 gene mutations have been
reported in autosomal form of NDI [2, 3].
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In an X-linked form of NDI, several clinical observations have
suggested that abnormalities of the renal vasopressin V2 receptor
(AVPR2) might underlie the unresponsiveness to AVP in this
disorder [4, 5]. Furthermore, chromosomal linkage analysis [6, 7]
and a functional expression study in somatic cell hybrids [8] have
demonstrated that the NDI locus and the V2 receptor gene can be
comapped to the distal region of the long arm of the X chromo-
some (Xq28), suggesting that the V2 receptor gene may be
candidate gene in pathogenesis of NDI. Molecular cloning of
human V2 receptor eDNA [9, 10] has allowed direct testing of the
hypothesis that genetic defects of the AVPR2 might be the
molecular basis for NDI. More than 64 distinct AVPR2 mutations
have been reported in NDI patients [11—24]. These mutations
including missense mutations, small deletionJinsertions, large
deletion and nonsense mutations leading to a truncated receptor
were widely distributed in the receptor polypeptide chain. The
variability of the AVPR2 mutations being identified in North
American ND! families [17, 20—22], has excluded the classical
Hopewell hypothesis that most North American ND! patients
share a common ancestor from among the Ulster Scot immigrants
who arrived in Nova Scotia in 1761 on the ship Hopewell [17, 25].
The V2 receptor is a member of the large family of seven
transmembrane spanning receptors which couple to a G protein.
Recent cloning of these receptors enables us to approach for
human diseases associated with defective 0 protein-coupled
receptors. However, such diseases are uncommon, presumably
reflecting the vital role of these receptors in development and
differentiation. Considering that a number of AVPR2 mutations
have been reported in NDI patients, NDI could be a potential in
vivo model of human disorders linked to defective G protein-
coupled receptor. Among various AVPR2 mutations so far re-
ported, only a small number of the mutants have been studied on
the receptor function [26—28]. R113W has been shown to have
combination of partial functional defects including binding capac-
ity, affinity, and coupling to a Gs protein [26], while R137H
mutation impaired adenylyl cyclase activation without affecting
binding affinity [27]. Moreover, other mutations (such as R181C)
have been also reported to impair receptor binding ability [28].
Such functional analysis of the mutant receptors in ND! individ-
uals will provide a basis for understanding of a receptor structure-
function relationship. Also, it would be ultimately necessary for
the curative therapeutic approach of this disorder.
In this study, we analyzed the V2 receptor gene in two
unrelated Japanese ND! kindreds and identified two AVPR2
mutations: a missense mutation R202C and a single base insertion
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8O4insG leading to a receptor truncation removing one third of
the carboxyl terminus. Although these mutations have been
reported in other NDI kindreds [20, 22,231, theirpotential effects
on receptor function have not as yet been examined. To investi-
gate the mechanisms by which these two mutations cause AVP
resistance, we expressed the mutants in mammalian cells and
assessed their functional properties as previously reported expres-
sion studies with other G protein-coupled receptors [29—32].
Transient transfection experiment with COS-7 cells demonstrated
that R202C mutant lost most of the binding activity but retained
about 15 to 30% of normal binding affinity and capacity, while a
8O4insG truncated receptor had no binding activity. Stable expres-
sion study with Chinese hamster ovary (CHO) cells showed the
R202C mutation abolished the ligand binding without affecting
receptor mRNA accumulation. The differences in binding prop-
erties observed for the R202C could reflect heterogeneous
AVPR2 expression in COS-7 cells. Specifically, COS-7 cells can
produce higher number of AVPR2 at the cell level than stably
transfected CHO cells, whereas their function may be partially
affected by untransfected cells resulting from limited transfection
efficiency. Our overall results from the two expression studies
suggest that the mutations could disrupt ligand-binding activity by
a post-transcriptional mechanism, thereby causing AVP resistance
in this disorder.
Methods
Subjects
Two unrelated Japanese kindreds were included in the study.
Patients were diagnosed with NDI on the basis of clinical mani-
festations consisting of a lifelong history of polyuria and polydip-
sia, normal or elevated plasma concentrations of arginine vaso-
pressin, and unconcentrated urine despite water deprivation and
exogenous administration of arginine vasopressin. None of the
patients had renal dysfunction other than AVP resistance. Pedi-
grees of the kindreds are shown in Figure 1. In kindreds I and II,
inheritance was consistent with an X-linked recessive mode.
Kindred I. A 19-year-old man (subject IV-6, in Fig. 1), who had
polyuria and polydipsia soon after birth, was evaluated for renal
function at the age of 3. Despite of plasma hyperosmolality (305
mmollkg), urinary osmolality was at extremely low level (120
mmollkg) and did not significantly increase in response to exog-
enous administration of AVP (140 mmollkg), leading to the
diagnosis of NDI. The plasma AVP level was inappropriately
elevated. Although polyuria had been controlled with a thiazide
diuretic, he eventually developed large atonic bladder and bilat-
Fig. 1. Pedigrees of NDI kindreds. A. Kindred I. B.
Kindred II. Circles with a central dot denote
obligatory carriers. Half-solid circles represent
clinically predicted carriers. Closed squares denote
affected males. A slash (I) through symbols
indicates that the subject is deceased. The proband
is shown by an arrow.
eral hydronephrosis as a consequence of polyuria. His mother
(subject 111-4) exhibited no DI symptoms, but a urine test was not
carried out. Four male family members spanning three genera-
tions suffered with the same disorder. His brother (subject IV-4)
died from severe dehydration after appendectomy.
Kindred II. The proband is a 21-year-old man (subject 11-1, in
Fig. 1) who was a full-term and normal delivery. His birth weight
was 2.9 kg. At the age of two months, he was referred for
consultation because of recurrent fever, vomiting, and failure to
gain weight normally. The diagnosis of NDI was made based on
plasma hyperosmolality (309 mmollkg), urinary hypoosmolality
(79 mmollkg), and the lack of urine concentration in response to
exogenous AVP stimulation (urinary osmolality, 50 to 60 mmol/
kg). His brother, a 20-year-old man (subject 11-2), also had
impaired urine concentrating ability: basal plasma and urinary
osmolality were 320 and 82 mmol/kg, respectively. Their mother
(subject 1-2) was asymptomatic and her daily urine volume was
about 2 to 3 liters. However, a 12-hour water deprivation test
displayed an incomplete urine concentration defect; urinary os-
molality and specific gravity were 330 to 375 mmollkg and 1.010 to
1.012, respectively, indicating that the mother had partial unre-
sponsiveness to AVP.
Genomic DNA amplification
Genomic DNA was obtained from white blood cells according
to standard procedures [33]. Three coding exons of the V2
receptor gene were amplified by PCR using oligonucleotide
primers [181. All primers were synthesized using a DNA synthe-
sizer (model 391A; Applied Biosystems, Foster City, CA, USA)
and purified with Oligonucleotide Purification Cartridges (Ap-
plied Biosystems). PCR was performed with Taq polymerase
according to the recommendation of Perkin-Elmer Cetus (Nor-
walk, CT, USA). Accordingly, the reaction was carried out in a
100 l volume containing 0.5 to 1.0 g of genomic DNA, 1.0 mi
MgCl2, 50mM KC1, 10 mrvi Tris-HC1 (pH 8.3), 150 M each dNTP,
2.5 U of Taq polymerase, and 50 to 100 pmole of each primer.
Amplification was performed for 30 to 35 cycles; each cycle
consisted of denaturation at 94°C for one minute, annealing at
55°C for 0.5 minutes, and extension at 72°C for two minutes.
Amplified PCR products were fractionated on and cut Out of a 3%
NuSieve GTG gel (FMC BioProducts, Rockland, ME, USA) and
then subjected to asymmetric PCR amplification.
SSCP analysis of PCR products
The SSCP analysis was performed according to the protocol of
Orita et al [34]. PCR amplification was carried in a 10 l reaction
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mixture that containing 50 to 100 ng of genomic DNA and 10
pmole of ['r32P]ATP end-labeled primers. Other PCR reaction
components were identical. One microliter of the PCR reaction
mixture was mixed with 9 1d of 95% formamide, 20 m EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol solution.
Immediately before electrophoresis, samples were heat-denatured
at 95°C for two minutes. One microliter of each 10 .d sample was
loaded onto a non-denaturing 5% polyacrylamide gel (49:1 acryl-
amide to N,N'-methylene-bis-acrylamide) containing 45 mivi Tris-
borate (pH 8.0) and 1 m'vi EDTA with or without 10% glycerol.
The gel was run at 30 W for four to six hours at room temperature
with cooling by a fan.
Direct sequencing of PCR products
Direct sequencing was performed as described by Kadowaki et
a! [35] with minor modifications. Specifically, annealing was
performed at a 1:1 ratio of primer to template, and single strand
binding (SSB) protein was used during the termination reaction to
prevent template secondary structure. Sequencing template was
obtained by the asymmetric PCR amplification method. The PCR
product was submitted to the amplification under similar condi-
tions, except either the sense or antisense primer was used. Free
nucleotides and primers were removed by centrifuge-driven dial-
ysis (Centricon-iQO Microconcentrator; Amicon Corp., Beverly,
MA, USA). The retentate which was used as a template was
vacuum dried and resuspended in 5 .d of water. One pmole of the
template was then annealed to an equal mole of sense or antisense
primer which was labeled with ['[32P]ATP (3000 Ci/mmol,
Amersham). Sequencing was performed by the dideoxy method
using Sequenase (United States Biochemical, Cleveland, OH,
USA) with the addition of 0.5 g of SSB protein (United States
Biochemical) to each dideoxy terminator/Sequenase mix. After
incubation with 0.1 g of proteinase K at 65°C for 20 minutes to
inactivate the SSB protein, the samples were run for four to seven
hours in a 5% polyacrylamide denaturing gel in 1 X Tris/borate!
EDTA (TBE) buffer (pH 8.0). The sequence was confirmed by
using at least two independently obtained PCR products.
Construction of wild-type and mutant V2 receptor
expression vectors
The full-length human V2 receptor cDNA (1.2 kb) was cloned
from a human kidney cDNA library (Clonetech, Palo Alto, CA,
USA) by the plaque hybridization technique and was subcloned
into pBluescript II KS(+), (Stratagene, La Jolla, CA, USA) at the
EcoRI site (pBS/V2R-W). A R202C substitution and a G inser-
tion in nt.804 to 809 were cloned from patient genomic DNA by
PCR amplification and restricted with NcoI and AlwNI. The
NcoI/A1wNI fragments were ligated into the corresponding sites
of pBSIV2R-W in exchange for the wild-type segment (pBS/V2R-
Cys and pBS/V2R-TRU). The sequences of the mutant pBS
constructs were determined to confirm the presence of the
expected mutation and to exclude misincorporation. For transient
expression in COS-7 cells, 1.2 kb XhoI/XbaI DNA fragments
comprising the full-length wild-type cDNA, and the two mutant
V2 receptor cDNAs were excised from pBS/V2R-W,-Cys, and
-TRU plasmids and were individually subcloned into the corre-
sponding polylinker sites of a pcDNAI eukaryotic expression
vector (Invitrogen, San Diego, CA, USA). For overexpression in
Chinese hamster ovary (CHO) cells, XhoI/XbaI digests of the
wild-type and mutant V2 receptor cDNAs obtained from pBS!
V2R constructs were filled in with the Klenow fragment of DNA
polymerase I and then ligated into the EcoRV site of the
pMT3DSV2 expression vector.
Expression of V2 receptor in mammalian cells
COS-7 monkey kidney cells were grown in Dulbecco's modified
Eagle's medium (DMEM) with 10% fetal bovine serum, 100 U/rn!
penicillin, and 100 g/ml streptomycin in an atmosphere of 5%
CO2 and 95% 02 at 37°C. Cells (5 X iO per 100 mm dish) were
transfected with 20 g of pcDNAI constructs by the calcium
phosphate precipitation technique [33]. After incubation for four
hours, the cells were shocked with 15% (vol/vol) glycerol in
DMEM at room temperature for one minute. Following further
incubation for 48 hours at 37°C, the transfected cells were scraped
off the dishes and assayed for radioligand binding activity. CHO
cells lacking the endogenous dihydrofolate reductase gene were
cultured in a minimal essential medium (aMEM, Gibco BRL,
Grand Island, NY, USA). Cells at a density of 7 X i05 were
cotransfected with 20 g of pMT3DSV2 constructs and 5 g of
pSV2neo by the calcium phosphate method. After incubation for
72 hours, cells were replated at a lower density into 60 mm dishes
and then selected with an antibiotic (G418 at 400 g/ml, Gibco) in
aMEM medium supplemented with 10% dialyzed fetal bovine
serum and without ribonucleoside and deoxyribonucleosides. Af-
ter two to three weeks, resistant colonies were selected and
subjected to stepwise amplification with increasing concentrations
of methotrexate (50 n to 200 nM, Sigma Chemical Co., St. Louis,
MO, USA) [36, 37].
Northern blotting
Total RNA prepared from CHO cells (20 pjg) was electropho-
resed on 1.0% agarose gel in the presence of 20 mt.s MOPS/5 mM
sodium acetate/i mM EDTA buffer (pH 7.0) and 7.4% formalde-
hyde. The RNA was transferred overnight to a nylon membrane
(Pall, Glen Cove, NY, USA) by capillary action using 10 x SSC
and then was baked at 80°C for two hours. The membrane was
subsequently hybridized overnight at 42°C in a 40% formamide
solution containing a 32P-labeled (1 X 106 cpm/ml) 0.9 kb human
V2 receptor cDNA probe (nucleotides 91 to 977). Blots were
washed twice for 15 minutes each in 2 X SSC/0.1% SDS at room
temperature and twice for 15 minutes each in 0.2 X SSC/0.1%
SDS at 50°C. After stripping, the blots were reprobed with f3-actin
cDNA as reported previously [38].
Radioligand binding assay
After cells transfected with either wild-type or mutant V2
receptor cDNA constructs were scraped off the culture plate,
membranes were prepared according to the method of Morel et al
[39]. The membrane fraction (10 to 50 g) was incubated in 200
1.d of an assay buffer (pH 7.4) containing 50mM Tris, 1 misi EGTA,
3 mM MgS0, 0.1% BSA, and 100 p.g/ml bacitracin with various
concentrations of [3H]-AVP (0.5 to 10 nivi; 78.2 Ci/mmol, Dupont-
New England Nuclear, Boston, MA, USA). Specific binding was
determined in the presence of 1 unlabeled AVP. After
incubation at 25°C for one hour, bound and free ligands were
separated by vacuum filtration using a Whatmann GF/C filter.
The radioactivity retained on the filter was counted in S ml of
aqueous counting scintillant (ACS II, Amersham Corp., Arlington
Heights, IL, USA). The Scatchard equation [bound/free =(BmI
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— (bound/Kd), where Bm and Kd are maximal binding site
density and affinity, respectively], was used to calculate K,d and
Bm, as reported previously [40].
Results
Sequencing and SSCP analysis of V2 receptor gene
Since AVPR2 gene mutations reported so far cluster in the
middle portion of the gene, SSCP analysis was done on the PCR
products encompassing the third extracellular and cytoplasmic
domains (nucleotide 615 to 856, 242 bps) for a rapid mutation
screening in affected individuals. This technique successfully
facilitated the detection of the AVPR2 gene mutation. The
proband of kindred I (subject IV-6, in Fig. 1A) displayed two
shifted bands which migrated slower than those of control sub-
jects, implying that the proband possessed a mutant allele (Fig.
2A). On the other hand, his mother (subject 111-4) exhibited three
bands which were not discretely separated, but essentially repre-
sented both the wild-type and mutant alleles. Likewise, in kindred
II, the proband (subject 11-1, Fig. 1B) showed two shifted bands,
while his mother (subject 1-2) represented four abnormally shifted
bands (Fig. 2B). These results of PCR-SSCP analysis revealed that
the patients harbored the mutation in a hemizygous fashion and
their mothers were heterozygous for the mutations, fitting with
the transmission mode of an X-linked inheritance. We next
examined the sequence by direct sequencing. In the proband of
kindred I (IV-6), a C to T transition was found at nucleotide
position 675, changing an amino acid Mg to Cys at codon 202.
(Fig. 3A) In his mother (IV-4), both the wild-type base (C) and
the mutated base (T) were shown at the same level of the
sequence ladder with a half of the normal density, indicating that
the mother was heterozygous for the mutation. In the proband of
kindred 11(11-1), a single base of guanine was inserted into two
consecutive GGG triplets (nucleotide 804 to 809), thereby causing
a frame shift beginning with codon 247 and premature termina-
tion at codon 258 (Fig. 3B). This mutation led to a truncation of
the receptor lacking nearly one third of its carboxyl portion. The
mother (1-2) was shown to have a mixture of normal and mutant
sequences, which was consistent with her partial resistance sug-
gested by a clinical urine test. The location of the mutations are
illustrated in Figure 4. The R202C and 8O4insG were located in
the third extracellular and third cytoplasmic domains, respec-
tively.
Expression and functional analysis of the mutant
We first attempted to transfect the wild-type, R202C and
8O4insG truncated form of AVPR2 gene constructs into COS-7
monkey kidney cell line, and examined their ligand binding
properties. Scatchard analysis of the wild-type V2 receptor re-
vealed a single class of binding sites with a dissociation constant
Kd = 1.1 0.1 nM and a total capacity Bm of 214 37 fmol/mg
protein (N = 7, mean SE). The receptor number was 2.0 to 3.0
x iO sites per cell and estimated as 2.0 to 6.0 x iO sites per cell
when corrected by the transfection efficiency (approximately 5 to
10% per total transfected cells in our laboratory). The binding
characteristics were almost compatible with data of transient
expression studies performed by other researchers [26, 42]. Mem-
brane from untransfected COS-7 cells did not display any binding
activity. A R202C mutant from COS-7 cell membranes exhibited
decreased binding activity with K. = 7.6 2.3 flM and Bm = 65
Fig. 2. PCR-SSCP analysis of the J'2 receptor gene. The middle portion of
AVPR2 gene (242 bps) was prepared from patient genomic DNA by PCR
amplification. The PCR products were denatured by heating at 95°C in
formamide loading buffer. One sl of the samples was electrophoresed on
a non-denaturing 5% polyacrylamide gel (49:1, actylamide to bis) contain-
ing 10% glycerol at room temperature at constant 30 W for 5 hours. A.
PCR-SSCP analysis for kindred I. Two bands abnormally migrated in the
patient (IV-6). In his mother (111-4), three bands, which did not separate
discretely as four bands, were detected. B. PCR-SSCP analysis for kindred
II. Compared with control subject, two shifted bands were detected in the
patient (11-1). Four bands, probably representing both the wild-type and
mutant alleles, were found in the mother (1-2). These results indicate that
the patients are hemizygous and their mothers are heterozygous for the
mutations.
47 fmol/mg protein (N =4, mean SE). The corrected mutant
receptor number was 5.0 X iO to 1.5 X iO sites per cell. In
contrast, the 8O4insG truncated receptor in COS-7 cells did not
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Fig. 3. PCR -direct sequencing of the 1/2 receptor
gene. PCR products of the AVPR2 gene
prepared by asymmetric PCR were used for a
template for sequencing. A. Sequencing for
kindred I subjects. The patient (IV-6) had a C to
T transition at nucleotide 675, changing Arg to
Cys at codon 202 (R202C). His mother (111-4)
had both a C and T base at the same level of the
sequence ladder, implying heterozygosity. B.
Sequencing for kindred II subjects. In the patient
(IL-i), sequencing of sense strand of the PCR
products showed a single guanine insertion in two
consecutive GGG triplets (nucleotide 804 to 809),
resulting in a frame shift from codon 247 and
stop codon at 258 (8O4insU). In his mother (1-2),
sequencing of antisense strand of the PCR
products depicted both normal and frame shift
sequence resulting from the U base insertion.
show any binding activity. However, it was difficult to assess
accurate binding affinity of the R202C mutant, because the level
of expression is limited and heterogeneous.
For further characterization of the R202C mutant, we at-
tempted to overcome this problem by generating stable cell lines
with high level expression of the AVPR2, using methotrexate-
induced gene coamplification in dihydrofolate reductase deficient
CHO cells. Wild-type and mutant V2 receptor cDNAs were
subeloned into the pMT3DSV2 vector and cotransfected with
pSV2neo into the dihydrofolate reductase-deficient CHO cells.
Following G418 selection and amplification with up to 200 nrvi
methotrexate, several cell lines became resistant and were
screened for AVPR2 expression by the radioligand binding assay
together with mRNA detection. The ligand binding assay demon-
strated that the receptor density of CHO cells expressing AVPR2
was comparable to that of COS-7 cells, when the expression of the
latter is corrected by transfection efficiency. Before a more precise
functional comparison of the wild-type and mutant receptors, the
V2 receptor mRNA content of each cell line was determined to
adjust the amount of mRNA. A rapid screening by a reverse
transcription PCR showed that mutant elonal cells produced
AVPR2 mRNA almost similar levels to that of the wild-type cell
lines (data not shown). Northern blotting using a 0.9kb human V2
receptor eDNA probe showed approximately 2.0 kb mRNA. The
mRNA level of each clone expressing the wild-type receptor
grossly correlated with the binding capacity for AVP as revealed
by the ligand binding assay (data not shown). The clones desig-
nated as C/W-i, and C/Cys-1, which expressed the comparable
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frame shift from 247-stop at 258
240 245 250 255 200
Fig. 4. Locations of the mutations in the human
V2 receptor. The putative seven transmembrane
structures of the AVPR2 are depicted on the
basis of the previously reported cDNA sequence
[9], and the sites of mutations are indicated. The
amino terminus is predicted to face the
extracellular space and contains a potential N-
linked glycosylation site at Asn22. Two possible
palmitoyl anchoring sites at Cys341,342 in the 4th
cytoplasmic domain are also illustrated. A.
Kindred I mutation. A R202C is located in the
third extracellular domain. Two conserved Cysll2
and Cys192, which are predicted to form disulfide
bond, are indicated by circles with a central dot.
B. Kindred II mutation. A single G insertion
(8O4insG) at either codon 245 or 246 lies in the
third cytoplasmic domain. This mutation causes a
frame shift changing amino acid sequences from
codon 247 to 257 (s), eventually incorporating a
stop codon at amino acid position 258. The lower
panel shows a missense sequence generated by
the mutation (11 amino acids indicated by
asterisks). Amino acids are numbered in
accordance with Birnbaumer et al [9].
amounts of mRNA, were selected from the wild-type and R202C
mutant clone pools, respectively, to compare the functional
properties of the V2 receptor (Fig. 5).
Figure 6 shows saturation binding of [3H}-AVP to membranes
from C/W-1, C/Cys-l cells as well as Scatchard analyses. The Kd
value of C/W-1 cell (Kd = 1.6 0.5 nM, N = 4) was fairly
comparable to that of COS-7 cells transfected with the wild-type
V2 receptor cDNA. C/W-1 cells expressed the V2 receptors at a
density of 1.2 X i0 sites per cells and stimulated more than 10-
to 15-fold increase of cAMP production from baseline in response
to 10 nM AVP (data not shown). On the other hand, four separate
[3H]-AVP binding experiments of CICys-1 cells failed to detect
any binding activity. At least two other clonal CHO cells express-
ing either wild-type or mutant receptors exhibited essentially
similar binding properties for AVP, suggesting that it is unlikely
that the impaired binding capacity was due to clonal variation of
receptor density (data not shown).
Discussion
Our expression study demonstrated that two mutations, R202C
and 8O4insG, impair the ligand binding activity of the V2 receptor,
thereby causing renal tubular resistance of ND!. A 8O4insG
mutant devoid of one third of the carboxyl terminus of the
AVPR2 showed undetectable binding when transiently expressed
in COS cells. The abolished ligand binding would be sufficient to
account for the clinical phenotype of a defective urine concentra-
tion ability. Since clinical defects in ND! patients are invariably
complete, AVPR2 gene mutations found in affected individuals
should result in nonfunctional protein. It is noteworthy that nearly
one third of the V2 receptor gene mutations reported in ND!
A
NH2 Extracellular
Arg202 — Cys
Intracellular
COOH
B
Intracellular
Extracellular
stop
COOH
A18S '.0'
18S •—0
B
.110— V2R
mRNA
*— 3Actinit RNA
560 Tsukaguchi et al: Expression of two A VPR2 mutants
Fig. S. Northern blot analysis of V2 receptor mRNA in CHO cells. Total
RNA (20 sg) isolated from CIW-1 and C/Cys-1 cells was electrophoresed
on 1.0% agarose gel and transferred to a nylon membrane. The blots were
hybridized with a [32P] dCTP-labeled 0.9kb V2 receptor cDNA probe (A),
indicating that the two cells produced comparable amount of AVPR2
mRNA. The same blot was then stripped and rehybridized with a /3-actin
probe (B) to confirm that equal amounts of mRNA were loaded onto each
lane.
patients lead to a receptor truncation. This is in contrast to the
fact that 39 of the 43 rhodopsin mutants, naturally occurring G
protein-coupled receptor mutations in patients with autosomal
dominant retinitis pigmentosa, result in amino acid substitution
[30]. Taken together, it is suggested that NDI mutations might
substantially lead to non-functional protein, therefore causing a
typical complete concentrating defect.
It should be noted that R202C mutant showed different degrees
of impairment in the two cell systems, COS-7 and CHO cells for
transient and stable expression, respectively. R202C mutant in
COS-7 cells retained some binding activity, whereas that in CHO
cells had no binding ability. One explanation for the partial
defects of the R202C mutant in COS-7 cells is that AVPR2 could
be overproduced, even beyond physiological levels. Since COS-7
cells have inherent machinery for plasmid replication (that is, T
antigen) [41], they could produce extremely high numbers of
AVPR2 at the cell level. Nevertheless, because of limited trans-
fection efficiency, the net AVPR2 production from COS cells may
be lower than stably transfected CHO cells, in which each cell
expressed almost equivalent amount of AVPR2. Thus, the high
level but heterogeneous expression in COS cells may mask the
natural effects of the AVPR2 mutation. Such discrepant biochem-
ical properties in the transient and stable expression have been
shown in another AVPR2 mutation R113W [26]. This mutation
reduced binding capacity to 20% of normal in COS cells, but not
affected receptor expression in stably transfected murine L cells.
The extent to which the R113W mutant activate adenylyl cyclase
was not significantly affected in COS cells, but was decreased by
threefold in L cells. Thus, careful interpretation is necessary to
assess physiological effects of the NDImutation in vivo. Since our
expression study with CHO cells showed that the R202C mutant
cell line exhibited undetectable binding for AVP, it is likely that
major functional effects of the R202C could be impairment of
ligand binding. However, to confirm our results, immunocyto-
chemistry or Western blotting analysis for epitope-tagged recep-
tor [28] and expression with another vector-host cell system, in
which AVPR2 production is regulated as a native kidney collect-
ing duct cell, would be necessary.
Since our study showed that receptor mRNA levels of the
mutants are unaffected, the mutation could disrupt receptor
ligand-binding through a post-transcriptional mechanism. How-
ever, it is still unclear whether the defective protein is produced,
or it reaches the plasma membrane. The study with epitope-
tagged AVPR2 mutants [28] has shown that an extracellular Cys
creating mutant R181C can be transported to the cell surface.
Such receptor localization would be useful to categorize the NDI
mutations as follows: (i) binding-deficient mutant which is prop-
erly assembled in the membrane but cannot be accessed to the
ligand; (ii) unstable mutant which is less effectively inserted into
the plasma membrane and/or more rapidly degraded than the
normal receptor; and (iii) transport deficient mutant which is
trapped by intracellular organelles such as the endoplasmic
reticulum. Such post-transcriptional and/or post-translational
modifications have been reported in naturally occurring rhodop-
sin mutants in patients with autosomal dominant retinitis pigmen-
tosa [29, 30]. In this disorder, these mutants have been divided
into two distinct phenotypic classes based on their intracellular
localization. Some mutants have been shown to be transported to
the plasma membrane, while others are partially or completely
trapped in the endoplasmic reticulum. Systemic analysis of other
NDI mutations using a receptor specific-antibody or epitope
tagging technique will be required to examine whether a similar
mechanism underlies the pathophysiology of NDI. Further study
along this line is now in progress.
Interestingly, most of the missense mutations in the third
extracellular domain are substitutions that incorporate a new
cysteine residue (R181C, G185C, R202C, and Y205C) [12, 13].
Human V2 receptor has two cysteine residues (Cysll2 and
Cys192, in the second and third extracellular domain, respec-
tively) which are conserved in the vasopressin/oxytocin receptor
subfamily [42, 43], suggesting that they are critical to structural or
functional integrity of the receptors. As demonstrated in other G
protein-coupled receptors such as rhodopsin and f3-adrenergic
receptors [29—32], these Cys residues form a disullide bond(s)
between the two extracellular loops and are possibly involved in
tertiary structure of the receptor and ligand binding. A critical
role of extracellular Cys residue was also confirmed by a previous
Fig. 6. Saturation curve and Scatchard plot of [3H]-
AVP binding to membranes from CHO cells
expressing the wild-type and mutant receptors. A.
Saturation binding experiments were performed
with increasing concentrations of [3H]-AVP in the
presence or absence of 1 jiM unlabeled AVP.
Specific binding of the wild-type as well as R202C
mutant is shown as (•, CIW-1) and (0,
C/Cys-1), respectively. Data are representative of 3
to 4 separate experiments. B. Scatchard linear
transformation of the data. The insert represents
enlargement of the plots by one order (bound AVP
2 is expressed as fmol mg). The experiment was
performed in duplicate and done at least three
times, each yielding similar results.
study with B-adrenergic receptor, demonstrating that thiol reduc-
ing agents inactivated the receptor function, presumably by cleav-
ing the disulfide bond [31]. Thus, it is speculated that an addi-
tional cysteine residue incorporation into the extracellular loop
could disrupt correct protein folding through forming de novo
disulfide bonds.
Identification of the V2 receptor gene mutation in a large
number of NDI individuals will provide further insights into the
structural-function relationship of a G protein-coupled receptor
and eventually enable mapping the key amino acid for receptor
function. Furthermore, we believe that a detailed molecular
classification of the defects will facilitate the future development
of therapeutic strategy for affected individuals.
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